| Prev Close | 1.28 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.67 / 6.50 |
| Avg Volume | 3.30M |
| Exchange | NASDAQ |
| Shares Outstanding | 101.01M |
| Market Cap | 131.31M |
| EPS | 1.40 |
| P/E Ratio | 0.87 |
| Div & Yield | N.A. (N.A) |
Latest News
Mannkind in Free Fall After Changes to Insulin Product, Sales Force
Shares of insulin maker Mannkind plummeted on news of a proposed stock split, staffing changes and a new iteration of its insulin.
Mannkind Stock Drops Following Changes to Its Insulin Product
Mannkind stock is suffering, and the company appears to be in trouble.
Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open
Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.
Insulin Drug Offers Hope for MannKind
The stock has taken a beating, but users of Afrezza are loyal to the drug.
2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
TheStreet's biotech columnist offers his own report card on biotech stocks.
2016 Was a Terrible Year for Biotech but the Tweets Were on Point
A look back at the year's worth of Adam Feuerstein's biotech tweets.
These 5 Stocks Under $10 Could Make You a Lot of Money
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
In Case You Missed It Thursday: Everyone (but Pfizer) May Still Need Some Advil
Donald Trump's victory may be a win for Wall Street traders; Colgate-Palmolive remains on slippery slope; and more from TheStreet and its various properties.
MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing
MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.
MannKind Corporation Reports 2016 Third Quarter Financial Results
- Conference Call to Begin Today at 5:00 PM ET -
Tax-Loss Selling Offers Stock-Picking Opportunities
Our screen reveals 17 names that could become oversold and disconnected from their fundamentals as a result of this phenomenon.
First Week of December 16th Options Trading For MannKind (MNKD)
Investors in MannKind Corp saw new options begin trading this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new December 16th contracts and identified the following put contract of particular interest.
Will Insiders Be Tempted To Buy More MNKD At The New 52-Week Low?
In trading on Friday, shares of MannKind Corp touched a new 52-week low of $0.61/share. That's a $3.18 share price drop, or -83.91% decline from the 52-week high of $3.79 set back on 10/28/2015.
Notable Wednesday Option Activity: MNKD, IDI, BYD
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MannKind Corp , where a total of 77,659 contracts have traded so far, representing approximately 7.8 million underlying shares. That amounts to about 183% of MNKD's average daily trading volume over the past month of 4.2 million shares.
